$ALM

Almonty clears final hurdle to start producing tungsten concentrate in South Korea

Almonty Industries (ALM) received South Korean approval to process tungsten concentrate at the Sangdong mine, expected to produce 200,000 MTU/year. The mine resumed production in March and has 4.4M MTU contracted. Tungsten is vital for defense and tech, with prices high and Chinese exports controlled. ALM shares rose 5.9% to $14.66.

Original reporting
Published Sep 21, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Almonty clears final hurdle to start producing tungsten concentrate in South Korea — source image
Decision brief

The 30-second read

$ALMBullishMed
01

Why it matters

Regulatory approval removes the final hurdle for commercial concentrate production, unlocking a 200,000 MTU/year capacity and supporting existing offtake contracts.

02

Market read

The approval is a catalyst for Almonty’s production timeline and may influence broader critical‑minerals equities as supply diversification gains focus.

03

What to watch

Long‑term offtake contracts lock in volume but may limit upside if spot prices surge beyond contract levels.

Relevance 8/10Novelty 8/10Timing: pre‑market Monday

Background

Almonty Industries (NASDAQ: ALM) operates the Sangdong tungsten mine in South Korea, a high‑grade asset poised to supply defense‑critical tungsten.

Company-level read

Ticker impact

$ALMBullishHigh confidence
Context

Almonty Industries received final South Korean regulatory approval to commercially process tungsten concentrate, unlocking production start.

Expected impact

Short-term upside as shares already jumped ~6%; medium-term bullish as production ramps in 2027.

Evidence & confidence

First‑report approval removes a major execution risk; the market reacted positively, indicating traders can act now.

Market effects

Boosts the critical‑minerals and defense materials sector, highlighting supply‑chain diversification away from China.

Strengthens South Korea's position in the tungsten market and may attract related mining investments.

Provides a Western‑addressed source of tungsten, relevant for U.S. defense procurement rules effective 2027.

Counterpoint

Production ramp may face technical delays; tungsten price rally could soften if Chinese output rebounds.

Key entities

  • Almonty Industries

    US‑listed tungsten mining company receiving approval.

  • Global Tungsten & Powders LLC

    Austria’s Plansee Group subsidiary with a 21‑year, 4.4 M MTU offtake agreement.

Related articles

$ALMMed

Defense Stockpile Orders Send Explorers Back to Old Tungsten Camps

The U.S. Defense Logistics Agency awarded a $2B contract for tungsten supplies, with a $450M investment from the Department of War. GoldHaven Resources (CSE: GOH) completed drilling at its Kuhn tungsten-skarn target, intersecting skarn mineralization in two locations. Almonty Industries (NASDAQ: ALM) began commercial operations at its Sangdong plant, with 90% of Phase I production contracted. Guardian Metal (NYSE: GMTL) reported drilling results from its Tempiute project.

$ELMTMed

Technology Metals Report (10.04.2026): A Summit Without a Rare Earth Deal Leaves the West Buying Its Way to Supply

The U.S. and China failed to reach a rare earth supply deal during Xi Jinping's visit, leaving the West to secure supplies. Rare earth exports from China to the U.S. declined, with prices showing mixed trends. Elmet Group and Almonty Industries are expanding tungsten production. Glencore will partner with the U.S. strategic minerals reserve. Eramet plans to expand lithium production in Argentina. Processing capacity is also increasing, with Korea Zinc planning a U.S. smelter.

$ALMMed

Almirall, S.A.: Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

Almirall, S.A. (ALM) presented new clinical data at EADV 2026, showcasing advances in dermatology treatments. Key findings include sustained improvements in atopic dermatitis with lebrikizumab and benefits in psoriasis with tildrakizumab. The company also highlighted its commitment to medical dermatology through sponsorship and awareness campaigns.

$ALMMed

Almonty Industries ALM Stock Rallies On Tungsten Breakout

Almonty Industries (NASDAQ: ALM) stock rose 11.09% on positive tungsten market news and project progress. The company reported $42.99M in quarterly revenue, $1.22B in cash, and a share buyback plan. ALM secured inspection certificates for its Sangdong project in South Korea and expanded operations in Rwanda, positioning itself as a key tungsten supplier outside China.

$ALMHigh

Why is Almonty Industries stock rallying today?

Almonty Industries (ALM) stock rose 2.7% in pre-market trading to $12.74. Stifel initiated coverage with a Buy rating and $25 target, while Goldman Sachs gave a Neutral rating and $13 target. The company's Sangdong mine in South Korea received final certification for commercial operations, securing 90% of Phase I output under long-term agreements. The S&P 500, Dow Jones, and Nasdaq were up 0.3%, 0.3%, and 0.5% respectively.